Study aim: Colchicine efficacy and safety on clinical symptoms improvement in patients with COVID-19 Design: Two arm parallel group randomized, double blind clinical trial on 110 patients. Permuted block will be used for randomization. Settings and conduct: Adult patients( over 18 years) with COVID-19 diagnosis according inclusion criteria and have been admitted to to Ibn Sina Hospital, randomly assigned to colchicine or placebo. Both groups will receive therapeutic regimen including subcutaneous injection of 250 microgram interferon beta 1b every other day and remdesivir 200 mg for first day then 100 mg daily for 5 days, Physician, patients and assessor will be blinded. Participants/Inclusion and exclusion criteria: Inclusion criteria are adults over the age of 18 with a diagnosis of COVID-19 based on clinical criteria or PCR Exclusion criteria: The presence of any underlying disease that increases the likelihood of side effects from colchicine Intervention groups: The recruited patients will be candidate to receive colchicine of Modava pharmaceutical company or placebo for one week according to randomization table. Colchicine will be administered 2 milligrams as loading dose and then one milligram daily for seven days and in control group placebo tablets with same size and color will be administered. Placebo will produce in pharmacy faculty. Main outcome variables: Determination of colchicine effects on clinical improvement of COVID-19 symptoms